The purpose of value-based insurance is to design copays, coinsurance, deductibles and other benefit features that will encourage people to use services that have been demonstrated to be cost-effective, while discouraging use of services for which there is less certain evidence of beneficial effects. These designs have been around long enough now that researchers have examined their effects on both quality and costs. An article in Health Affairs reviews the results of these early studies. (Health Affairs Article) All of the studies focused on prescription drugs, which typically have elaborate copay designs. Thirteen studies were selected, all of which involved copayment reductions on drugs that treated chronic diseases. The studies were all considered to have good to excellent methodological quality. All of the studies showed an improvement in medication adherence after one year, by an average of 3%. Some showed continuing adherence gains beyond one year. The adherence response varied across drug types. Several of the studies examined a potential effect of copay reductions on medical and drug spending. As might be expected, drug spending rose. The effect on overall health spending was less clear, but appeared to be an insignificant change, up or down although some individual studies showed an increase and some a decrease. Two studies looked at utilization and found decreases in ER use, physician visits and hospitalizations. An important future goal of research should be to track overall spending and utilization changes in the long run.
Value-based Insurance Results
By Kevin RocheJuly 25, 2013Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 25, 2023
Coronamonomania Lives Forever, Part 201
Tired of March Madness? A boringly refreshing dip into some CV-19 research summaries is recommended.
March 24, 2023
The CDC Is a Font of Methodological and Statistical Error
Several times in the last three years I and others have pointed out serious flaws…
March 24, 2023
A Couple of Health Care Notes
A couple of pieces of health care research focus on high health care spending and…